Archive for November, 2017

02 Nov1 The retractions came only months after BioMed Central.

Charlotte J. Haug, M Transcranial Direct Stimulation .D., Ph.D.1 The retractions came only months after BioMed Central, an open-access publisher owned by Springer, retracted 43 content articles for the same reason. How can you really fake peer review? Moon, who studies medicinal plant life, had set up a simple treatment. He gave journals recommendations for peer reviewers for his manuscripts, providing them with e-mail and brands addresses. But these addresses were ones he created, therefore the requests to review visited him or his co-workers directly. Read more…

02 Nov300 low-income Floridians on waiting lists to gain access to lifesaving AIDS medications.

In addition, pharmacies will provide shipping and delivery services for patients who need it. AHF and other participating pharmacies will agree to waive all dispensing charges and other applicable costs linked to these services. With an increase of than one-third the full total number of people on ADAP waiting around lists nationwide, we see this as a practical alternative to Florida’s growing Helps medication crisis.’ Under AHF’s proposal, at the Condition level, clients who meet the criteria will be described this program by ADAP personnel: The patient will bring his / her prescription together with the wait list verification letter to a participating pharmacy of which they’ll fill their prescriptions. Read more…

01 NovAasma Shaukat.

Geisser, M.S., Frank A. Lederle, M.D., John H. Bond, M.D., Jack S. Mandel, Ph.D., M.P.H., and Timothy R. Church, Ph.D.: Long-Term Mortality after Screening for Colorectal Cancer Estimates from multiple, large, randomized trials of colorectal-tumor screening with fecal occult-blood testing consistently display a decrease in colorectal-malignancy mortality of 15 to 33 percent.1-4 The longest follow-up reported to day is 18 to 20 years.5-7 Whether the aftereffect of screening on colorectal-tumor mortality is sustained and whether it pertains to all age groups and both sexes are unfamiliar. Furthermore, non-e of the trials have shown a reduction in all-cause mortality, and one meta-analysis demonstrated a significant increase in mortality not linked to colorectal cancer.8 We updated the Minnesota CANCER OF THE COLON Control Study9 through 30 years of follow-up to assess the long-term aftereffect of screening on colorectal-cancer mortality and all-cause mortality also to evaluate effects specific to age and sex. Read more…